Open AccessESRRG promoter hypermethylation as a diagnostic and prognostic biomarker in laryngeal squamous cell carcinoma
Author(s) -
Shen Zhisen,
Hu Yan,
Zhou Chongchang,
Yuan Jie,
Xu Jie,
Hao Wenjuan,
Deng Hongxia,
Ye Dong
Publication year - 2019
Publication title -
journal of clinical laboratory analysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.536
H-Index - 50
eISSN - 1098-2825
pISSN - 0887-8013
DOI - 10.1002/jcla.22899
Subject(s) - methylation , biomarker , dna methylation , medicine , bisulfite sequencing , receiver operating characteristic , oncology , cancer research , stage (stratigraphy) , carcinoma , survival analysis , promoter , pathology , gene , biology , gene expression , paleontology , biochemistry
Background Estrogen‐related receptor gamma ( ESRRG ) has been identified as a tumor suppressor gene in several cancers. We aimed to evaluate ESRRG promoter methylation in laryngeal squamous cell carcinoma (LSCC) and its relative clinical value in LSCC. Methods Bisulfite pyrosequencing assays were performed on 91 pairs of tumor and paracancer tissues from LSCC patients in China. The diagnostic value and overall survival (OS) were analyzed descriptively by receiver operating characteristic (ROC) curves and the Kaplan‐Meier methods, respectively. Results The ESRRG promoter was more frequently hypermethylated in tumor tissues than in adjacent tissues ( P < 0.01). ESRRG promoter methylation was significantly increased in advanced T stage tumors ( P < 0.01) and advanced clinical stage patients ( P < 0.01). Moreover, the area under the ROC curve (AUC) value (0.81) indicated high discrimination accuracy. Furthermore, ESRRG hypermethylation was associated with poor OS, as confirmed by Kaplan‐Meier survival curves ( P < 0.01). Conclusion Our study indicated that ESRRG promoter hypermethylation contributed to LSCC‐related risks, primarily tumor progression and survival prognosis, in patients. ESRRG promoter methylation could, therefore, be a diagnostic and prognostic biomarker in LSCC.